VitaVent

The company has submitted a patent application for a new invention that uses Oxycyte™ perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. The patent application is also an improvement of the existing Fluorovent patent the company already possesses.

The invention, VitaVent™, provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be easily used by a person who has suffered a heart attack or stroke, but is still conscious, without the assistance of another. It may also be used easily by someone who cannot adequately perform CPR in order to assist someone who is unconscious.

By safely combining Oxycyte and oxygen in a device without pressure, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim’s lungs an oxygen load that is 50 times greater than what the same volume of blood is able to carry. The concept of this invention is to administer oxygen-enriched Oxycyte through the lungs to reach oxygen-deprived tissues even when circulation is obstructed and/or a person has stopped breathing.

The company believes this device could be sold over the counter and be present wherever there is a defibrillator as well as in any home where there is concern about a potential heart attack or stroke for a loved one.